المؤلفون: Walbaum, Benjamin, Acevedo, Francisco, Medina, Lidia, Bravo, M. Loreto, Merino, Tomas, Camus, Mauricio, Dominguez, Francisco, Mondaca, Sebastian, Galindo, Hector, Nervi, Bruno, Ibañez, Carolina, Madrid, Jorge, Peña, Jose, Koch, Erica, Garrido, Marcelo, Pinto, Mauricio P., Sánchez, César

المصدر: Current Medical Research & Opinion; Jul2020, Vol. 36 Issue 7, p1195-1199, 5p

مصطلحات موضوعية: HEALTH facilities, HORMONE therapy, PEMETREXED, BREAST cancer, PROTEIN metabolism, THERAPEUTIC use of antineoplastic agents, CELL receptors, RETROSPECTIVE studies, BREAST tumors

مصطلحات جغرافية: CHILE

مستخلص: Objective: Clinical guidelines recommend the use of endocrine therapy (ET) in advanced hormone receptor positive (HR+) human epidermal growth factor receptor type 2 negative (HER2-) breast cancer (BC) patients in the absence of visceral disease or ET resistance. Furthermore, studies indicate similar response and survival rates using ET or cytotoxic chemotherapy (CT).Methods: Herein, we assessed clinical characteristics, type of systemic therapy and survival rates of advanced HR + HER2-BC patients in our database.Results: A total of 172 advanced HR + HER2-BC patients were treated at our institution between 1997 and 2019. Sixty percent received first-line ET (4% received combined ET). Median age of this subset was 55 years (range: 30-86). Similarly, the median age of patients that received CT was 54 years (range: 21-83). Over time, 30% of patients received ET in the 2000-2005 period; this increased to 70% in the 2016-2019 period (p = .045). Overall survival (OS) was 97 months and 51 months for patients treated with ET or CT, respectively (p = .002).Conclusions: To the best of our knowledge this is the first study assessing the use of ET in Chilean advanced HR + HER2-BC patients. Several patients in our institution receive CT without indication. The increase in ET usage over time can be attributed to better and faster immunohistochemical detection methods for Estrogen Receptor (ER), changes in educational and government policies, and a wider variety of ET options. Finally, clinical trials have failed to demonstrate a substantial benefit of CT over ET in this setting. [ABSTRACT FROM AUTHOR]

: Copyright of Current Medical Research & Opinion is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Owen, Gareth I, Pinto, Mauricio P, Retamal, Ignacio N, Fernádez, María F, Cisternas, Betzabe, Mondaca, Sebastian, Sanchez, Cesar, Galindo, Hector, Nervi, Bruno, Ibañez, Carolina, Acevedo, Francisco, Madrid, Jorge, Peña, José, Bravo, Maria Loreto, Maturana, Maria Jose, Cordova-Delgado, Miguel, Romero, Diego, de la Jara, Nathaly, Torres, Javiera, Rodriguez-Fernandez, Maria

المصدر: Medicine; Apr2018, Vol. 97 Issue 16, p1-8, 8p

المؤلفون: Carrillo, Diego, Erazo, Alonso, Peña, Jose, Bravo, Maria Loreto, Pinto, Mauricio, Muñoz, Pablo, Zoroquiain, Pablo, Valbuena, Jose, Hevia, Joaquin, Goic, Carolina, Robles, Christian, Solovera, Maria Eliana, Salas, Patricio, Bannura, Felipe, Galindo, Hector

المصدر: Journal of Thoracic Oncology; 2023 Supplement, Vol. 18, pS10-S10, 1p

المؤلفون: Quezada, Nicolás, Acevedo, Francisco, Marambio, Andrés, León, Felipe, Galindo, Hector, Roa, Juan Carlos, Jarufe, Nicolás

المصدر: International Journal of Surgery Case Reports; Oct2014, Vol. 5 Issue 10, p681-685, 5p

مستخلص: INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future. [ABSTRACT FROM AUTHOR]

: Copyright of International Journal of Surgery Case Reports is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Solis, Luisa M., Behrens, Carmen, Raso, M. Gabriela, Lin, Heather Y., Kadara, Humam, Yuan, Ping, Galindo, Hector, Tang, Ximing, Lee, J. Jack, Kalhor, Neda, Wistuba, Ignacio I., Moran, Cesar A.

المصدر: Cancer (0008543X); Jun2012, Vol. 118 Issue 11, p2889-2899, 11p

مصطلحات موضوعية: LUNG cancer, ADENOCARCINOMA, HISTOLOGY, TRANSCRIPTION factors, TUMORS

مستخلص: BACKGROUND: Lung adenocarcinoma is histologically heterogeneous and has 5 distinct histologic growth patterns: lepidic, acinar, papillary, micropapillary, and solid. To date, there is no consensus regarding the clinical utility of these patterns. METHODS: The authors performed a detailed semiquantitative assessment of histologic patterns of 240 lung adenocarcinomas and determined the association with patients' clinicopathologic features, including recurrence-free survival (RFS) and overall survival (OS) rates. In a subset of tumors, expression levels of 2 prognostic molecular markers were evaluated: thyroid transcription factor-1 (TTF-1) (n = 218) and a panel of 5 proteins (referred as the FILM signature index) (n = 185). RESULTS: Four mutually exclusive tumor histology pattern groups were identified: 1) any solid (38%), 2) any papillary but no solid (14%), 3) lepidic and acinar but no solid or papillary (30%), and 4) acinar only (18%). Patients in group 3 had a higher RFS rate than patients in group 1 (hazard ratio [HR], 0.4510; P = .0165) and group 2 (HR, 0.4253; P = .0425). Solid pattern tumors (group 1) were associated with a lower OS rate than nonsolid pattern tumors (all stages: HR; 1.665; P = .0144; stages I and II: HR, 2.157; P = .008). In the patients who had tumors with a nonsolid pattern, high TTF-1 expression was associated significantly with higher RFS (HR, 0.994; P = .0017) and OS (HR, 0.996; P = .0276) rates in all stages, and a high FILM signature index score was associated with lower RFS and OS rates in all stages (RFS: HR, 1.343; P = .0192; OS: HR, 1.371; P = .0156) and in stages I and II (RFS: HR, 1.419; P = .0095; OS: HR, 1.315; P = .0422). CONCLUSIONS: The presence of a solid histologic pattern was identified as a marker of unfavorable prognosis in patients with primary lung adenocarcinoma. High TTF-1 expression and low FILM signature index scores were associated with a better prognosis for patients who had tumors with a nonsolid pattern. Cancer 2011;. © 2011 American Cancer Society. [ABSTRACT FROM AUTHOR]

: Copyright of Cancer (0008543X) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Sen, Banibrata, Shaohua Peng, Ximing Tang, Erickson, Heidi S., Galindo, Hector, Mazumdar, Tuhina, Stewart, David J., Wistuba, Ignacio, Johnson, Faye M.

المصدر: Science Translational Medicine; 5/30/2012, Vol. 4 Issue 136, preceding p1-11, 11p

المؤلفون: Cordova-Delgado, Miguel, Pinto, Mauricio P., Retamal, Ignacio N., Muñoz-Medel, Matías, Bravo, María Loreto, Fernández, María F., Cisternas, Betzabé, Mondaca, Sebastián, Sanchez, César, Galindo, Hector, Nervi, Bruno, Ibáñez, Carolina, Acevedo, Francisco, Madrid, Jorge, Peña, José, Koch, Erica, Maturana, Maria José, Romero, Diego, de la Jara, Nathaly, Torres, Javiera

المصدر: Cancers; Sep2019, Vol. 11 Issue 9, p1275-1275, 1p

مصطلحات موضوعية: CANCER patients, EPSTEIN-Barr virus, IMMUNOTHERAPY, MORTALITY, ONCOGENES, STATISTICS, STOMACH tumors, TRANSFERASES, TISSUE arrays, GENE expression profiling, DESCRIPTIVE statistics

مصطلحات جغرافية: CHILE

مستخلص: Gastric cancer (GC) is a heterogeneous disease. This heterogeneity applies not only to morphological and phenotypic features but also to geographical variations in incidence and mortality rates. As Chile has one of the highest mortality rates within South America, we sought to define a molecular profile of Chilean GCs (ClinicalTrials.gov identifier: NCT03158571/(FORCE1)). Solid tumor samples and clinical data were obtained from 224 patients, with subsets analyzed by tissue microarray (TMA; n = 90) and next generation sequencing (NGS; n = 101). Most demographic and clinical data were in line with previous reports. TMA data indicated that 60% of patients displayed potentially actionable alterations. Furthermore, 20.5% were categorized as having a high tumor mutational burden, and 13% possessed micro-satellite instability (MSI). Results also confirmed previous studies reporting high Epstein-Barr virus (EBV) positivity (13%) in Chilean-derived GC samples suggesting a high proportion of patients could benefit from immunotherapy. As expected, TP53 and PIK3CA were the most frequently altered genes. However, NGS demonstrated the presence of TP53, NRAS, and BRAF variants previously unreported in current GC databases. Finally, using the Kendall method, we report a significant correlation between EBV+ status and programmed death ligand-1 (PDL1)+ and an inverse correlation between p53 mutational status and MSI. Our results suggest that in this Chilean cohort, a high proportion of patients are potential candidates for immunotherapy treatment. To the best of our knowledge, this study is the first in South America to assess the prevalence of actionable targets and to examine a molecular profile of GC patients. [ABSTRACT FROM AUTHOR]

: Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Salas, Patricio¹, Solovera, Maria Eliana¹, Bannura, Felipe¹, Muñoz-Medel, Matias², Cordova-Delgado, Miguel², Sanchez, Cesar², Ibañez, Carolina², Garrido, Marcelo², Koch, Erica², Acevedo, Francisco², Mondaca, Sebastian², Nervi, Bruno², Madrid, Jorge², Peña, Jose², Pinto, Mauricio P.², Valbuena, José³, Galindo, Hector² investigacion.onco@uc.cl

المصدر: Ecancermedicalscience. 2021, Vol. 15 Issue 1162-1202, p1-8. 8p.

مصطلحات موضوعية: *PROGNOSIS, *MYASTHENIA gravis, *THYMUS tumors, *OVERALL survival, *SURVIVAL rate, *TUMORS

مصطلحات جغرافية: UNITED States

مستخلص: Background: Thymic epithelial tumours are rare and highly heterogeneous. Reports from the United States suggest an overall incidence of 0.15 per 100,000/year. In contrast, the incidence of these tumours in Latin America is largely unknown and reports are scarce, somewhat limited to case reports. Methods: Herein, we report a series of 38 thymic tumours from a single institution, retrospectively incorporated into this study. Patient characteristics and outcomes including age, sex, stage, paraneoplastic syndromes, treatment regimens and the date of decease were obtained from medical records. Results: Most cases in our series were females and young age (<50 years old) and early stage by Masaoka-Koga or the Moran staging systems. Also, a 34% of patients had myasthenia gravis (MG). Next, we analysed overall survival rates in our series and found that the quality of surgery (R0, R1 or R2), MG status and staging (Masaoka-Koga, Moran or TNM) were prognostic factors. Finally, we compared our data to larger thymic tumour series. Conclusions: Overall, our study confirms complete surgical resection as the standard, most effective treatment for thymic epithelial tumours. Also, the Masaoka-Koga staging system remains as a reliable prognostic factor but also the Moran staging system should be considered for thymomas. [ABSTRACT FROM AUTHOR]